荣昌生物公告,公司已完成2022年A股限制性股票激励计划中A类权益第二个及B类权益首次授予第一个归属期的归属工作,涉及16名A类和100名B类激励对象,共计归属27.6160万股。新增股份于2025年5月8日上市流通,总股本增至54460.824万股。本次归属不会对公司财务状况和经营成果构成重大影响。
Source Link荣昌生物公告,公司已完成2022年A股限制性股票激励计划中A类权益第二个及B类权益首次授予第一个归属期的归属工作,涉及16名A类和100名B类激励对象,共计归属27.6160万股。新增股份于2025年5月8日上市流通,总股本增至54460.824万股。本次归属不会对公司财务状况和经营成果构成重大影响。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.